- Datum24.02.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Kein Moderator verfügbar
Karyopharm Therapeutics Inc. Aktie
Verkaufen
Kaufen
Karyopharm Therapeutics Inc. Chart
Karyopharm Therapeutics Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-1,44 %
Intraday
-2,95 %
1 Woche
-13,05 %
1 Monat
-11,52 %
Seit Jahresbeginn
-51,74 %
1 Jahr
-94,30 %
3 Jahre
-96,28 %
5 Jahre
-97,89 %
10 Jahre
Wikifolio
Passender Service zu Karyopharm Therapeutics Inc.
Webinar zu Karyopharm Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,530-1,700
- Jahrestief / Hoch ($)0,530-0,830
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Karyopharm Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Karyopharm Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
